Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

BIZARRE: Generic revlimid fades but teva s broader generics outlook remains strong | Mind Blowing Facts

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will release its second-quarter 2025 financial results tomorrow, July 30.

According to Benzinga Pro, the company expects to report second-quarter earnings of 62 cents, with sales of around $4.29 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.